dexmedetomidine has been researched along with glutamic acid in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (18.75) | 29.6817 |
| 2010's | 9 (56.25) | 24.3611 |
| 2020's | 4 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Hertz, L; Huang, R; Yu, AC | 1 |
| Hertz, L; Huang, R | 1 |
| Goyagi, T; Masaki, Y; Nishikawa, T; Tobe, Y | 1 |
| Chiu, KM; Lin, TY; Lu, CW; Wang, SJ | 1 |
| Kan, MC; Li, JT; Ma, WQ; Wang, W; Wang, WP; Xie, T; Yao, GD | 1 |
| Mendelowitz, D; Sharp, DB; Wang, X | 1 |
| Gao, X; Gu, SL; Han, JP; Hu, B; Li, M; Ma, TF; Ma, X; Qin, SJ; Wu, YQ; Zhou, L | 1 |
| DU, CY; Feng, ZG; Wang, H; Yu, J; Zhang, H; Zhang, N; Zhang, WD | 1 |
| Lin, B; Lu, Y; Zhong, J | 1 |
| She, Y; Song, X; Xu, H; Zhao, B | 1 |
| Gao, L; Liu, H; Shan, Y; Tang, Z; Wang, X | 1 |
| Chiu, KM; Lee, MY; Lin, TY; Lu, CW; Wang, MJ; Wang, SJ | 1 |
| Feng, Z; Guo, M; Hu, Q; Ren, B; Tian, Y; Xie, Q; Xu, C; Yu, J; Zhang, W | 1 |
| Bao, N; Tang, B | 1 |
| Melonakos, ED; Nehs, CJ; Nikolaeva, KK; O'Brien, C; Rey, C; Siegmann, MJ; Solt, K | 1 |
| Ishiguro, M; Kakizaki, R; Narimatsu, E; Nomura, K; Sawamoto, K; Takahashi, K; Uemura, S | 1 |
1 review(s) available for dexmedetomidine and glutamic acid
| Article | Year |
|---|---|
Organ-Protective Effects and the Underlying Mechanism of Dexmedetomidine.
Topics: Adenylyl Cyclases; Adrenergic alpha-2 Receptor Agonists; Animals; Anti-Inflammatory Agents; Antioxidants; Apoptosis; Catecholamines; Dexmedetomidine; Glutamic Acid; GTP-Binding Proteins; Humans; Hypnotics and Sedatives; Inflammation; Neurotoxins; Oxidative Stress; Signal Transduction | 2020 |
15 other study(ies) available for dexmedetomidine and glutamic acid
| Article | Year |
|---|---|
Dexmedetomidine-induced stimulation of glutamine oxidation in astrocytes: a possible mechanism for its neuroprotective activity.
Topics: Adrenergic alpha-Agonists; Animals; Astrocytes; Brain Ischemia; Carbon Dioxide; Carbon Radioisotopes; Cells, Cultured; Cerebral Cortex; Dexmedetomidine; Glutamic Acid; Glutamine; Hypoxia, Brain; Mice; Neuroprotective Agents; Neurotoxins; Oxidation-Reduction | 2000 |
Receptor subtype and dose dependence of dexmedetomidine-induced accumulation of [14C]glutamine in astrocytes suggests glial involvement in its hypnotic-sedative and anesthetic-sparing effects.
Topics: Anesthetics; Animals; Astrocytes; Calcium; Carbon Radioisotopes; Cells, Cultured; Cerebral Cortex; Dexmedetomidine; Glutamic Acid; Glutamine; Hypnotics and Sedatives; Mice; Neurons; Receptors, Adrenergic, alpha-2; Synaptic Transmission | 2000 |
The combined neuroprotective effects of lidocaine and dexmedetomidine after transient forebrain ischemia in rats.
Topics: Anesthetics, Local; Animals; Blood Gas Analysis; Blood Pressure; Body Temperature; Brain Chemistry; Cerebrovascular Circulation; Dexmedetomidine; Drug Combinations; Glutamic Acid; Heart Rate; Hippocampus; Hypnotics and Sedatives; Ischemic Attack, Transient; Lidocaine; Male; Microdialysis; Neuroprotective Agents; Neurotransmitter Agents; Norepinephrine; Prosencephalon; Rats; Rats, Sprague-Dawley | 2009 |
Inhibitory effect of glutamate release from rat cerebrocortical nerve terminals by α2 adrenoceptor agonist dexmedetomidine.
Topics: 4-Aminopyridine; Adrenergic alpha-2 Receptor Agonists; Animals; Calcium; Calcium Channels, N-Type; Cerebral Cortex; Dexmedetomidine; Glutamic Acid; Male; MAP Kinase Signaling System; Membrane Potentials; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2; Synapses; Synaptosomes | 2011 |
Anticonvulsant effect of dexmedetomidine in a rat model of self-sustaining status epilepticus with prolonged amygdala stimulation.
Topics: Adrenergic alpha-2 Receptor Agonists; Amygdala; Animals; Anticonvulsants; Dexmedetomidine; Electric Stimulation; gamma-Aminobutyric Acid; Glutamic Acid; Glutathione; Hippocampus; Male; Malondialdehyde; Rats; Rats, Wistar; Status Epilepticus | 2013 |
Dexmedetomidine decreases inhibitory but not excitatory neurotransmission to cardiac vagal neurons in the nucleus ambiguus.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Animals; Dexmedetomidine; Dose-Response Relationship, Drug; gamma-Aminobutyric Acid; Glutamic Acid; Glycine; Heart; Medulla Oblongata; Neurons; Patch-Clamp Techniques; Rats, Sprague-Dawley; Tissue Culture Techniques; Vagus Nerve; Yohimbine | 2014 |
Dexmedetomidine prevents post-ischemic LTP via presynaptic and postsynaptic mechanisms.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Brain Ischemia; CA1 Region, Hippocampal; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Dexmedetomidine; Disease Models, Animal; Excitatory Postsynaptic Potentials; Glucose; Glutamic Acid; Long-Term Potentiation; Miniature Postsynaptic Potentials; Neuroprotective Agents; Norepinephrine; Protein Kinase Inhibitors; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Synapses; Tissue Culture Techniques | 2015 |
[Protective effect of dexmedetomidine against glutamate-induced cytotoxicity in PC12 cells and its mechanism].
Topics: Animals; Apoptosis; Calcium; Cell Survival; Dexmedetomidine; Glutamic Acid; Membrane Potential, Mitochondrial; Mitochondria; PC12 Cells; Rats; Reactive Oxygen Species | 2016 |
The Therapeutic Effect of Dexmedetomidine on Rat Diabetic Neuropathy Pain and the Mechanism.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Apoptosis; Cytokines; Dexmedetomidine; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Glutamic Acid; Hyperalgesia; Inflammation; Interleukin-1beta; Male; Microglia; Pain Threshold; Rats, Sprague-Dawley; Spinal Cord; Tumor Necrosis Factor-alpha; Yohimbine | 2017 |
Dexmedetomidine ameliorates lidocaine-induced spinal neurotoxicity via inhibiting glutamate release and the PKC pathway.
Topics: Adrenergic alpha-2 Receptor Agonists; Anesthetics, Local; Animals; Dexmedetomidine; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Glutamic Acid; Injections, Spinal; Lidocaine; Male; Protein Kinase C; Rats; Rats, Sprague-Dawley; Signal Transduction; Spinal Cord | 2018 |
Neuroprotective effects of dexmedetomidine against isoflurane-induced neuronal injury via glutamate regulation in neonatal rats.
Topics: Animals; Dexmedetomidine; Glutamic Acid; Injections, Intraperitoneal; Isoflurane; Male; Neurons; Neuroprotective Agents; Rats; Rats, Sprague-Dawley | 2019 |
Dexmedetomidine protects neurons from kainic acid-induced excitotoxicity by activating BDNF signaling.
Topics: Animals; Anticonvulsants; Apoptosis; Brain-Derived Neurotrophic Factor; Dexmedetomidine; Drug Evaluation, Preclinical; Glutamic Acid; Hippocampus; Kainic Acid; Male; MAP Kinase Signaling System; Nerve Tissue Proteins; Neurons; Neuroprotective Agents; NF-E2-Related Factor 2; Rats; Rats, Sprague-Dawley; Receptor, trkB; Seizures | 2019 |
Dexmedetomidine Attenuates Glutamate-Induced Cytotoxicity by Inhibiting the Mitochondrial-Mediated Apoptotic Pathway.
Topics: Animals; Apoptosis; Cell Survival; Cytochromes c; Dexmedetomidine; Glucose; Glutamic Acid; Membrane Potential, Mitochondrial; Mitochondria; Oxidative Stress; PC12 Cells; Protective Agents; Rats; Reactive Oxygen Species; Signal Transduction | 2020 |
Excitation of Putative Glutamatergic Neurons in the Rat Parabrachial Nucleus Region Reduces Delta Power during Dexmedetomidine but not Ketamine Anesthesia.
Topics: Anesthesia; Anesthetics, Dissociative; Animals; Calcium-Binding Proteins; Delta Rhythm; Dexmedetomidine; Glutamic Acid; Hypnotics and Sedatives; Ketamine; Male; Neurons; Parabrachial Nucleus; Rats; Rats, Sprague-Dawley | 2021 |
Dexmedetomidine improves excessive extracellular glutamate-induced synaptic depression (BRAINRES-D-21-00941).
Topics: Animals; Depression; Dexmedetomidine; Dobutamine; Glutamic Acid; Hippocampus; Isoproterenol; Rats; Receptors, Adrenergic; Synaptic Transmission | 2022 |